Sandra Sienkiewicz

Sandra Sienkiewicz

Auto-generated profile, based on publicly available information

Sandra Sienkiewicz

Provincial Hospital in Poznan, Poznań, Poland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
DSDominik Szklarkowski
Dominik Szklarkowski
KRKlaudia Romejko
Klaudia Romejko
WKWiktor Kubik
Wiktor Kubik
MGMichał Górski
Michał Górski
JNJan Nowak
Jan Nowak
GKGracjan Kosiorowski
Gracjan Kosiorowski
Introduction and objective: Edwards Syndrome, also known as Trisomy 18, is the second most common autosomal trisomy following Down Syndrome. This chromosomal disorder is characterized by the presence of a third copy of chromosome 18, in contrast to the usual two. The condition is associated with a wide spectrum of severe congenital anomalies, significant developmental delays, and a high rate of fetal loss and infant mortality. Therefore, a comprehensive synthesis of these associated developmental anomalies is crucial for accurate prenatal counseling, clinical guidance, and postnatal management. The primary objective of this comprehensive review is to systematically identify, collate, and synthesize the existing literature regarding the range and prevalence of congenital heart defects in children diagnosed with Edwards Syndrome. Recognizing that cardiac anomalies are a cardinal feature and a leading cause of mortality in this condition, this review aims to provide a detailed, evidence-based overview of these specific manifestations. Ultimately, this focused analysis seeks to enhance clinical understanding of the cardiovascular complications in Edwards Syndrome and inform targeted management strategies. Brief description of the state of knowledge: Edwards Syndrome (Trisomy 18) is characterized by a high burden of congenital anomalies, with cardiac defects affecting the vast majority of patients and serving as a primary determinant of survival. Historically regarded as a uniformly lethal condition requiring only palliative care, the clinical perspective is evolving. Recent data indicate that cardiac interventions may offer survival benefits, challenging traditional non-interventional paradigms and necessitating an updated understanding of the cardiovascular phenotype. Methods: A systematic literature review was performed by searching major biomedical databases (PubMed, Google Scholar, Elicit) using a combination of keywords and MeSH terms, including "Edwards Syndrome" and "congenital abnormalities." Inclusion criteria prioritized peer-reviewed articles such as case series, observational studies, and systematic reviews. Data extraction focused on the types, frequency, and systemic impact of anomalies, as well as postnatal developmental outcomes. The collected data were then synthesized to create a comprehensive syndrome profile. Conclusions: The clinical paradigm for Edwards Syndrome is shifting from a uniform designation of lethality toward a personalized, multidisciplinary model. Accurate prenatal diagnosis via fetal echocardiography is essential for early risk stratification. Contemporary management requires a balanced approach integrating palliative care with the option of active cardiac intervention. Consequently, parental counseling must emphasize shared decision-making, providing families with evidence-based data on potential surgical outcomes to optimize the quality of life for the affected child.

24 December 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
IKIllia Koval
Illia Koval
KRKlaudia Romejko
Klaudia Romejko
BKBarbara Kujawa
Barbara Kujawa
SSSandra Sienkiewicz
Sandra Sienkiewicz
JSJagoda Saniuk
Jagoda Saniuk
GKGracjan Kosiorowski
Gracjan Kosiorowski
This paper presents current knowledge on diabetes mellitus (ICD-10 E10-E14) and its clinical impact. Diabetes is a growing global problem, with over 3 million adults affected in Poland alone. The disease develops as type 1, caused by autoimmune destruction of pancreatic β-cells, or as type 2, driven mainly by insulin resistance and obesity. Both forms lead to impaired glucose uptake and abnormal fat and protein metabolism. Common symptoms include thirst, polyuria, fatigue, weight loss, and recurrent infections, though type 2 diabetes often remains silent for years. Persistent hyperglycemia promotes toxic metabolite accumulation, microangiopathy, neuropathy, and multiorgan complications. Cardiovascular manifestations, such as diabetic cardiomyopathy and arrhythmias, significantly increase morbidity and mortality. Early detection, lifestyle modification, and improved diagnostic strategies remain essential to reduce the burden of disease.

29 December 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
IKIllia Koval
Illia Koval
KRKlaudia Romejko
Klaudia Romejko
BKBarbara Kujawa
Barbara Kujawa
JSJagoda Saniuk
Jagoda Saniuk
SSSandra Sienkiewicz
Sandra Sienkiewicz
KWKacper Wojtala
Kacper Wojtala
This paper explores the rapidly increasing incidence of Parkinson's disease (PD) and the limitations of current dopamine-based therapies, which only address symptoms rather than underlying causes. This has spurred research into novel treatment approaches rooted in the disease's pathophysiology. A key pathological hallmark of PD is mitochondrial dysfunction, particularly affecting complex I, a critical component of cellular energy metabolism. This discovery has directed investigations toward individual elements of mitochondrial pathways, including the NAD+/NADH redox balance. Studies indicate reduced NAD+ levels in the brains of individuals with PD, prompting research into the therapeutic effects of NAD+ supplementation. This review summarizes recent scientific findings on how augmenting NAD+ and its derivatives may influence Parkinson's disease. It discusses the impact of NAD+ precursor supplementation on mitochondrial function and NAD+ levels in neurons carrying the GBA mutation. The paper also covers defects in PINK1 expression, their link to PD development, and the potential role of Nicotinamide (vitamin B3) in this context. Additionally, it assesses the safety of oral NAD+ precursor supplementation and its effects on brain NAD+ levels and metabolism in PD patients. A deeper understanding of PD pathophysiology and continued research into raising NAD+ levels are vital for developing novel therapeutic strategies. Modulating NAD+ holds significant promise as a supportive or disease-modifying therapy for this neurodegenerative condition.